Climb Bio, Inc.
CLYM•NASDAQ•Healthcare•Biotechnology

About Climb Bio

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOAoife Brennan
Founded2018
IPO DateAugust 10, 2021
Employees18
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websiteclimbbio.com
Phone866 857 2596
Address
20 William Street, Suite 145 Wellesley Hills, Massachusetts 02481 United States

Corporate Identifiers

CIK0001768446
CUSIP28658R106
ISINUS28658R1068
EIN83-2273741
SIC2834

Leadership Team & Key Executives

Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Chief Executive Officer, President and Director
Dr. Susan Altschuller M.B.A., Ph.D.
Chief Financial Officer
Chandra Adams J.D.
Vice President and General Counsel
Janaki M. Subramanyam M.Sc.
Vice President and Head of Regulatory Affairs
Kate Hecht M.B.A.
Senior Vice President of Program Management
Dr. Perrin Wilson B.S., Ph.D.
Chief Business Officer
Dr. Edgar D. Charles M.D., M.Sc.
Chief Medical Officer
Cindy J. Driscoll M.B.A.
Senior Vice President of Finance
Ashley Jones
SVice President of People and Workforce Strategy
Adam Villa
Senior Vice President of Technical Operations